MET-097i is an ultra-long-acting GLP-1 receptor agonist that was shown in a phase 1/2 trial to achieve 7.5% weight loss over 36 days and a 380-hour (nearly 16-day) half-life, which Metsera said ...

The weight-loss drug market is evolving at a rapid speed ... the body's energy expenditure and is currently in development. Metsera: Metsera (NASDAQ:MTSR) is developing oral and injectable ...

NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq ... dose four-fold higher than the weekly dose continued to lose weight, with an arithmetic mean placebo-subtracted change ...

SALT LAKE CITY, UTAH / ACCESS Newswire / February 27, 2025 / CenExel is pleased to announce its partnership with Metsera, Inc., a clinical-stage biopharmaceutical company dedicated to advancing ...

About Metsera Metsera is a clinical-stage biopharmaceutical ... targets and meet the future needs of a rapidly evolving weight loss treatment landscape. Metsera was founded in 2022 and is based ...

January 31, 2025 Metsera hits $2.7 bln valuation as shares surge 42% in Nasdaq debut Shares of weight-loss drug developer Metsera surged nearly 42% in a strong Nasdaq debut on Friday, valuing the ...

Oral peptide platform development on track with weight loss and tolerability data for ... dosing and improved tolerability. In February, Metsera completed an IPO, raising approximately $316.2 ...

MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs beginning mid-2025 Multiple data readouts in mid and ...